Atrium Therapeutics, Inc. (RNA) Stock Analysis
A live, multi-source view of Atrium Therapeutics, Inc. (RNA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Sector: Healthcare · Industry: Biotechnology · United States · atriumtherapeutics.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Atrium Therapeutics, Inc. (RNA) had a market capitalization of $242.7M (forward -1.8); the shares traded in a 52-week range of $11.13 – $16.77 (-3.8% over the year).
- Market cap
- $242.7M
- Enterprise value
- $-12.5M
- Forward P/E
- -1.8
- Price / book
- 1.04
- EPS (trailing)
- $-5.44
- EPS (forward)
- $-8.06
- Payout ratio
- 0.0%
- 52-week range
- $11.13 – $16.77
- 52-week change
- -3.8%
- Average volume
- 181,734
- Shares outstanding
- 17.1M
- Profit margin
- -184.1%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Atrium Therapeutics, Inc. (RNA) last closed at $10.35 (the last completed close before that scan).
Technicals at the scan: RSI 31 (neutral territory), price -21.2% versus its 20-day average, 20-day versus 50-day average spread +4.5%, MACD histogram -0.40.
Sentiment inputs: StockTwits 100% bullish; Reddit mentions 0% over 24 hours; analyst consensus score 75/100.
Next scheduled company event: in 59 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for RNA in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
RNA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Atrium Therapeutics, Inc. (RNA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell RNA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.